FIELD: medicine, pharmaceutics.
SUBSTANCE: declared group of inventions relates to medicine. There are declared methods of treatment and preventive treatment of prostate cancer in males and a method for treatment of prostate cancer in male dogs involving a single agent therapy in the form of introducing a therapeutic amount of N,N'-bis(2,3-butadienyl)-1,4-butane-diamine or its pharmaceutically acceptable salt or solvate. The therapeutic amount is specified within the range from 1-100 mg/kgbody weight and dosed within the range from twice a week to once a day.
EFFECT: group of inventions has high therapeutic efficacy.
26 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIARYL-SPIROHYDANTOIC COMPOUNDS USEFUL IN HYPERPOLIFERATIVE DISORDER TREATMENT | 2012 |
|
RU2668972C2 |
| LOW-MOLECULAR INHIBITORS OF N-TERMINUS ACTIVATION OF ANDROGEN RECEPTOR | 2009 |
|
RU2519948C2 |
| DIARYLTHIOHYDATOIC COMPOUNDS | 2007 |
|
RU2449993C2 |
| DETECTING PAX2 FOR DIAGNOSING BREAST CANCER | 2009 |
|
RU2522485C2 |
| THERAPEUTIC AGENTS BASED ON DIGLYCYLYL ETHER DERIVATIVES AND METHODS FOR USING THEM | 2009 |
|
RU2572596C2 |
| METHOD FOR USE OF N,N'-BIS(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | 2017 |
|
RU2667123C1 |
| FLUORINATED DERIVATIVES OF 4-AZASTEROID AS ANDROGEN RECEPTOR MODULATORS | 2003 |
|
RU2320670C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
